| Ytd | 39.03% | |
| 1y | 82.27% |
| Open | 16.05 | Prev Close | 16.02 | Low | 16.00 | High | 16.66 | Mkt Cap | 2.10B |
| Vol | 1.39M | Avg Vol | 2.39M | EPS | -0.40 | P/E | N/A | Forward P/E | 48.22 |
| Beta | 1.78 | Short Ratio | 10.10 | Inst. Own | 115.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 17.44 | 200-d Avg | 12.43 | 1yr Est | 21.55 |
NEO News
Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announc
NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on gr
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report)'s stock price reached a new 52-week high during tr
Wall Street analysts raised targets for PTC, Cloudflare, PENN, Microsoft and others, while downgradi
StoneX analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the pric
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price ta
NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testi
Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net p
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday'
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price ta
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.05 per share which beat the analyst conse
Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the p
NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic so
Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx ident
In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for sett
solutions that enable precision medicine, announced today that it has commenced a private offering o
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec
Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price t
Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Ou
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.01 per share which met the analyst consen
Through this integration, physicians can order NeoGenomics' comprehensive suite of tests, spanni
Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Chec